HC Wainwright Issues Pessimistic Forecast for GH Research (NASDAQ:GHRS) Stock Price

GH Research logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright cut its price target on GH Research from $65 to $55 but maintained a Buy rating; its new target implies 193.33% upside from the stock’s then-current price.
  • Analyst sentiment remains broadly positive: the consensus rating is Moderate Buy, with an average price target of $43.45. Ten analysts rate the stock Buy, one Hold, and one Sell.
  • GH Research reported a quarterly loss of $0.18 per share, narrower than the $0.31 loss analysts expected. Shares opened at $18.75 on Tuesday and were down 1.8%.
  • Five stocks to consider instead of GH Research.

GH Research (NASDAQ:GHRS - Get Free Report) had its price objective reduced by investment analysts at HC Wainwright from $65.00 to $55.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's target price suggests a potential upside of 193.33% from the company's current price.

A number of other equities analysts have also commented on the company. Cantor Fitzgerald lifted their price objective on GH Research from $35.00 to $40.00 and gave the stock an "overweight" rating in a research note on Friday, August 7th. Guggenheim increased their target price on GH Research from $34.00 to $40.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Zacks Research upgraded GH Research from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 13th. Needham & Company LLC raised their target price on GH Research from $32.00 to $39.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Finally, New Street Research set a $65.00 price target on GH Research in a research report on Monday, August 10th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $43.45.

Check Out Our Latest Analysis on GH Research

GH Research Trading Down 1.8%

NASDAQ:GHRS opened at $18.75 on Tuesday. GH Research has a 1 year low of $12.04 and a 1 year high of $31.44. The firm's fifty day simple moving average is $22.11 and its 200 day simple moving average is $21.65. The firm has a market capitalization of $1.29 billion, a PE ratio of -19.74 and a beta of 1.31.

GH Research (NASDAQ:GHRS - Get Free Report) last announced its earnings results on Friday, November 13th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.13. As a group, analysts anticipate that GH Research will post -1.20 EPS for the current fiscal year.

Institutional Trading of GH Research

Several hedge funds and other institutional investors have recently bought and sold shares of GHRS. Bellevue Group AG acquired a new position in shares of GH Research during the third quarter valued at about $109,000. Marshall Wace LLP grew its position in GH Research by 46.3% during the third quarter. Marshall Wace LLP now owns 68,298 shares of the company's stock worth $1,604,000 after buying an additional 21,601 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in GH Research during the third quarter worth about $82,000. China Universal Asset Management Co. Ltd. increased its stake in GH Research by 30.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 17,525 shares of the company's stock valued at $432,000 after acquiring an additional 4,106 shares during the period. Finally, Farther Finance Advisors LLC increased its stake in GH Research by 9,720.0% during the third quarter. Farther Finance Advisors LLC now owns 9,820 shares of the company's stock valued at $231,000 after acquiring an additional 9,720 shares during the period. 56.90% of the stock is currently owned by institutional investors and hedge funds.

About GH Research

(Get Free Report)

GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.

Read More

Analyst Recommendations for GH Research (NASDAQ:GHRS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GH Research Right Now?

Before you consider GH Research, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.

While GH Research currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines